Chongqing Genrix Biopharmaceutical (688443) 广发证券·2024-12-04 01:09Investment Rating - The report assigns a "Buy" rating to the company [6]. Core Insights - The company is a leading domestic player in autoimmune diseases, with an innovative pipeline driving long-term growth. It focuses on three major therapeutic areas: autoimmune diseases, infectious diseases, and oncology, with a robust pipeline targeting potential pathways such as IL-17A, IL-4R, TSLP, and CD3xBCMA [4][27]. - The launch of the first domestically approved IL-17 monoclonal antibody, Xeligekimab, is expected to drive significant sales growth, with a peak sales estimate of 2 billion yuan [4][43]. - The GR1802 monoclonal antibody targeting IL-4R is in advanced clinical stages and has a broad indication space, with peak sales expected to exceed 1.7 billion yuan [5][16]. - The company has a strong R&D foundation with 15 products in development, including several innovative monoclonal and bispecific antibodies, indicating a solid long-term growth potential [5][36]. Summary by Sections Company Overview - Established in 2015, the company is an innovative biopharmaceutical firm focused on addressing significant clinical needs through antibody drug discovery technology [27]. Product Pipeline - The company has a diverse pipeline with 15 products under development across autoimmune diseases, infectious diseases, and oncology, with a focus on key targets such as IL-17A, IL-4R, and IFNAR1 [36][38]. Financial Projections - Revenue projections for 2024-2026 are 56 million, 191 million, and 501 million yuan, respectively, with expected EPS of -2.28, -2.05, and -1.47 yuan per share [5][10]. The estimated fair value of the stock is 38.09 yuan per share [6].